Stefanie Howell

OverviewAI-generated summary

Stefanie Howell's research group at the University of Arkansas for Medical Sciences focuses on understanding the molecular mechanisms underlying viral infections and neurological disorders. Her recent work includes the development of covalent chemical probes to inhibit cysteine proteases, specifically targeting the Chikungunya virus nsP2 protease. These probes have demonstrated antialphaviral activity and proteome-wide selectivity, indicating potential for broad-spectrum antiviral applications. Howell's group also investigates the impact of sleep disturbances on recovery following traumatic brain injury (TBI) and stroke. Their studies examine how sex differences in sleep architecture may affect short-term episodic memory and overall recovery after TBI, and they have analyzed sleep architecture and apnea patterns in patients recovering from supra- and infratentorial strokes, comparing outcomes between hemorrhagic and ischemic events. Additionally, her group has explored the relationship between GLP-1 use in obese populations and the development of Barrett's esophagus.

Howell has received federal funding for her work, including a $489,570 grant from the NIH/National Heart, Lung, and Blood Institute as Principal Investigator. This project focuses on the prevention of heart failure induced by Doxorubicin through the early administration of Dexrazoxane. Her research network includes collaborations with Samantha Robinson at the University of Arkansas for Fayetteville and C. D. Collins at the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications. Howell's scholarship is characterized by 28 publications and a h-index of 5, with 86 total citations.

Metrics

• h-index: 5
• Publications: 28
• Citations: 86